DDInter396 DDInter797
Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Gadoteric acid, commonly used in the salt form gadoterate meglumine, is a macrocyclic, ionic gadolinium-based contrast agent (GBCA). It is composed of the organic acid DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) used for its chelating properties, and gadolinium (Gd3+). Gadoterate meglumine has one of the highest thermodynamic stability, apparent stability, and kinetic stability, partly due to its macrocyclic structure, and thus has a more favorable safety profile due to a decreased tendency of gadolinium dechelation.[A263141,A263106] Gadoterate is approved by the FDA under the brand name DOTAREM on 20th March 2013 for intravenous uses with magnetic resonance imaging (MRI) in the brain (intracranial), spine, and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood-brain barrier (BBB) and/or abnormal vascularity.
Clevidipine {u} (Compound) resembles {v} (Compound) Nicardipine
Nicardipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gadoteric acid
Clevidipine {u} (Compound) resembles {v} (Compound) Nicardipine
Nicardipine {u} (Compound) resembles {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gadoteric acid
Clevidipine {u} (Compound) resembles {v} (Compound) Nifedipine
Nifedipine {u} (Compound) resembles {v} (Compound) Nicardipine
Nicardipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gadoteric acid
Clevidipine {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Nicardipine
Nicardipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gadoteric acid
Clevidipine {u} (Compound) is included by {v} (Pharmacologic Class) Calcium Channel Antagonists
Calcium Channel Antagonists {u} (Pharmacologic Class) includes {v} (Compound) Nicardipine
Nicardipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gadoteric acid
Clevidipine {u} (Compound) causes {v} (Side Effect) Acute coronary syndrome
Acute coronary syndrome {u} (Side Effect) is caused by {v} (Compound) Verapamil
Verapamil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gadoteric acid
Clevidipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Clevidipine (Compound) resembles Nicardipine (Compound) and Nicardipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Clevidipine (Compound) resembles Nifedipine (Compound) and Nifedipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Clevidipine (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Clevidipine (Compound) is included by Calcium Channel Antagonists (Pharmacologic Class) and Calcium Channel Antagonists (Pharmacologic Class) includes Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Clevidipine (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Verapamil (Compound) and Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid